Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Jawaher, Hussain, Syed A, Ansari, Asif, Glaholm, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588609/
https://www.ncbi.nlm.nih.gov/pubmed/23467578
http://dx.doi.org/10.2147/BTT.S25862
_version_ 1782261595765735424
author Ansari, Jawaher
Hussain, Syed A
Ansari, Asif
Glaholm, John
author_facet Ansari, Jawaher
Hussain, Syed A
Ansari, Asif
Glaholm, John
author_sort Ansari, Jawaher
collection PubMed
description A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.
format Online
Article
Text
id pubmed-3588609
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35886092013-03-06 Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma Ansari, Jawaher Hussain, Syed A Ansari, Asif Glaholm, John Biologics Review A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear. Dove Medical Press 2013 2013-02-28 /pmc/articles/PMC3588609/ /pubmed/23467578 http://dx.doi.org/10.2147/BTT.S25862 Text en © 2013 Ansari et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ansari, Jawaher
Hussain, Syed A
Ansari, Asif
Glaholm, John
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_full Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_fullStr Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_full_unstemmed Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_short Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
title_sort critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588609/
https://www.ncbi.nlm.nih.gov/pubmed/23467578
http://dx.doi.org/10.2147/BTT.S25862
work_keys_str_mv AT ansarijawaher criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma
AT hussainsyeda criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma
AT ansariasif criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma
AT glaholmjohn criticalappraisalofaxitinibinthetreatmentofadvancedrenalcellcarcinoma

Ejemplares similares